Literature DB >> 22160242

Scram1 is a modifier of spinal cord resistance for astrocytoma on mouse Chr 5.

Jessica Amlin-Van Schaick1, Sungjin Kim, Karl W Broman, Karlyne M Reilly.   

Abstract

Tumor location can profoundly affect morbidity and patient prognosis, even for the same tumor type. Very little is known about whether tumor location is determined stochastically or whether genetic risk factors can affect where tumors arise within an organ system. We have taken advantage of the Nf1-/+;Trp53-/+cis mouse model of astrocytoma/glioblastoma to map genetic loci affecting whether astrocytomas are found in the spinal cord. We identify a locus on distal Chr 5, termed Scram1 for spinal cord resistance to astrocytoma modifier 1, with a LOD score of 5.0 and a genome-wide significance of P < 0.004. Mice heterozygous for C57BL/6J×129S4/SvJae at this locus show less astrocytoma in the spinal cord compared to 129S4/SvJae homozygous mice, although we have shown previously that 129S4/SvJae mice are more resistant to astrocytoma than C57BL/6J. Furthermore, the astrocytomas that are found in the spinal cord of Scram1 heterozygous mice arise in older mice. Because spinal cord astrocytomas are very rare and difficult to treat, a better understanding of the genetic factors that govern astrocytoma in the spine may lead to new targets of therapy or prevention.

Entities:  

Mesh:

Year:  2011        PMID: 22160242      PMCID: PMC3299925          DOI: 10.1007/s00335-011-9380-0

Source DB:  PubMed          Journal:  Mamm Genome        ISSN: 0938-8990            Impact factor:   2.957


  31 in total

Review 1.  Prognostic factors in intramedullary astrocytomas: a literature review.

Authors:  Vladimír Benes; Pavel Barsa; Vladimír Benes; Petr Suchomel
Journal:  Eur Spine J       Date:  2009-06-28       Impact factor: 3.134

2.  A novel model of intramedullary spinal cord tumors in rats: functional progression and histopathological characterization.

Authors:  Justin Caplan; Gustavo Pradilla; Alia Hdeib; Betty M Tyler; Federico G Legnani; Carlos A Bagley; Henry Brem; George Jallo
Journal:  Neurosurgery       Date:  2006-07       Impact factor: 4.654

3.  Incidence patterns for primary malignant spinal cord gliomas: a Surveillance, Epidemiology, and End Results study.

Authors:  Steven Hsu; Marisa Quattrone; Quinn Ostrom; Timothy C Ryken; Andrew E Sloan; Jill S Barnholtz-Sloan
Journal:  J Neurosurg Spine       Date:  2011-03-11

4.  Regulation of membrane-type 4 matrix metalloproteinase by SLUG contributes to hypoxia-mediated metastasis.

Authors:  Chi-Hung Huang; Wen-Hao Yang; Shyue-Yih Chang; Shyh-Kuan Tai; Cheng-Hwei Tzeng; Jung-Yie Kao; Kou-Juey Wu; Muh-Hwa Yang
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

5.  Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis.

Authors:  B A Mock; M M Krall; J K Dosik
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

6.  Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects.

Authors:  Karlyne M Reilly; Robert G Tuskan; Emily Christy; Dagan A Loisel; Jeremy Ledger; Roderick T Bronson; C Dahlem Smith; Shirley Tsang; David J Munroe; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-19       Impact factor: 11.205

Review 7.  The plasminogen activator inhibitor "paradox" in cancer.

Authors:  Bernd R Binder; Judit Mihaly
Journal:  Immunol Lett       Date:  2008-05-02       Impact factor: 3.685

8.  Spinal glioma: platelet-derived growth factor B-mediated oncogenesis in the spinal cord.

Authors:  Yasuyuki Hitoshi; Brent T Harris; Huan Liu; Brian Popko; Mark A Israel
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

9.  Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q.

Authors:  M R Stratton; D Ford; S Neuhasen; S Seal; R Wooster; L S Friedman; M C King; V Egilsson; P Devilee; R McManus
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

10.  Erythropoietin promotes spinal cord-derived neural progenitor cell proliferation by regulating cell cycle.

Authors:  Y Wang; M Yao; C Zhou; D Dong; Y Jiang; G Wei; X Cui
Journal:  Neuroscience       Date:  2010-02-16       Impact factor: 3.590

View more
  5 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

Review 2.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

Review 3.  Contextual signaling in cancer.

Authors:  Laura J Smithson; Corina Anastasaki; Ran Chen; Joseph A Toonen; Sidney B Williams; David H Gutmann
Journal:  Semin Cell Dev Biol       Date:  2016-06-03       Impact factor: 7.727

4.  Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.

Authors:  Kelly A Diggs-Andrews; Jacquelyn A Brown; Scott M Gianino; Joshua B Rubin; David F Wozniak; David H Gutmann
Journal:  Ann Neurol       Date:  2014-02-06       Impact factor: 10.422

5.  Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.

Authors:  Alexander Pemov; Heejong Sung; Paula L Hyland; Jennifer L Sloan; Sarah L Ruppert; Andrea M Baldwin; Joseph F Boland; Sara E Bass; Hyo Jung Lee; Kristine M Jones; Xijun Zhang; James C Mullikin; Brigitte C Widemann; Alexander F Wilson; Douglas R Stewart
Journal:  PLoS Genet       Date:  2014-10-16       Impact factor: 5.917

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.